Your current location is set to United States. If this is incorrect, please change your location:
Background: It is estimated that half of all individuals with multiple sclerosis (MS) experience chronic pain. Chronic ‘neuropathic’ pain is particularly distressing, because conventional analgesic therapies are largely ineffective or are associated with dose-limiting side effects. The development of... Read the full article
Summary: The onset of MS prior to age 18, during pivotal periods of cognitive maturation and development, has a profound impact on the child and their family. A fundamental unmet need is to understand the impact of pediatric-onset MS (POMS) and the recently identified myelin oligodendrocyte glycoprotein... Read the full article
Summary: Myelin is a fatty substance that protects nerve cells and acts to enhance their signal transmission. MS results from abnormal activity of the immune system whereby the body’s own immune cells target and damage myelin and myelin-producing cells called oligodendrocytes located in the central... Read the full article
Summary: One of the unmet needs is a better understanding of, and treatment options for, progression in MS. While current therapies in MS aim to slow the progression of the disease, there are no treatment options that successfully alter the trajectory of progression. A key to altering progression in... Read the full article
Summary: Inflammasomes are protein complexes in the immune system that are activated by infection. These complexes are also activated in multiple sclerosis (MS) and promote inflammation and brain injury. The factors regulating inflammasomes in progressive MS are unclear. The research team will: Identify... Read the full article
